Real-World Outcomes and Healthcare Utilization of Lanadelumab in Spain: Insights from First Cohort of Difficult-to-Treat Hereditary Angioedema Cases

    February 2025 in “ Allergies ”
    Inmaculada Sánchez‐Machín, Ruperto González‐Pérez, Elena Mederos‐Luis, Sara García-Gil, Paloma Poza‐Guedes
    TLDR Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.
    This study evaluated the real-world impact of lanadelumab on patients with hereditary angioedema (HAE) at Hospital Universitario de Canarias in Spain. The results showed a significant reduction in healthcare resource utilization, with a 75.3% decrease in hospital visits and a 94.1% reduction in angioedema episodes. The use of on-demand icatibant treatment decreased by 61%, and quality of life scores improved from 62.2 to 99.5. Lanadelumab proved to be an effective long-term prophylactic treatment with minimal adverse effects, significantly enhancing the quality of life for HAE patients.
    Discuss this study in the Community →